Version history

{
  "session_id": "sess_SDA-BIOMNI-BINDER_D-0657a9ed",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "mini-max",
  "action": "support",
  "content": "\n\n# Practical Feasibility Assessment: α-Synuclein Aggregation Inhibitors\n\n## Executive Summary\n\nAfter evaluating the four hypotheses against current scientific, technical, and clinical realities, I propose the following survival recommendations:\n\n| Hypothesis | Survival | Rationale |\n|------------|----------|-----------|\n| H1: NACore β-sheet interface | **CONDITIONAL** — reframe as fibril elongation inhibitor, not nucleation",
  "tokens_used": "107"
}